Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 9/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23568566 | 0.98 | KEAP1 (0.47) | KEAP1CA2CA1CA9CA12 | |
| SCHEMBL23569845 | 0.85 | KEAP1 (0.43) | KEAP1CA2CA1CA9CA12 | |
| SCHEMBL4973829 | 0.82 | KEAP1 (0.42) | KEAP1CA2CA1PKMACHE | |
| SCHEMBL13592488 | 0.80 | KEAP1 (0.46) | KEAP1CA2CA1PKMACHE | |
| SCHEMBL1760843 | 0.80 | TRPV4 (0.42) | KEAP1CA2CA1PKMACHE | |
| SCHEMBL2980809 | 0.79 | KEAP1 (0.42) | KEAP1CA2CA1PKMACHE | |
| SCHEMBL12261098 | 0.77 | MAPT (0.44) | KEAP1PKMPOLBTSHRMAPK1 | |
| SCHEMBL20562744 | 0.77 | KMT2A (0.47) | CA2CA1CA9CA12PKM | |
| SCHEMBL12087010 | 0.74 | HTR6 (0.54) | KEAP1PKMPOLBTSHRMAPK1 | |
| SCHEMBL14271818 | 0.73 | ALDH1A1 (0.49) | KEAP1POLBTSHRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697354-B1 | ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-1745032-B1 | CXCR1 and CXCR2 chemokine antagonists | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7691856-B2 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-04-06 | — | — | US | disclosed |
| US-7671212-B2 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1551818-B1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| EP-1694659-B8 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1694659-B1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-7338968-B2 | Thiadiazoles AS CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1697354-A1 | ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1694659-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060025453-A1 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20060014794-A1 | CXCR1 and CXCR2 chemokine antagonists | SCHERING CORPORATION | 2006-01-19 | — | — | US | disclosed |
| WO-2005113534-A2 | CXCR1 AND CXCR2 CHEMOKINE ANTAGONISTS | SCHERING CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005068460-A1 | ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005066147-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1551818-A1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | Pharmacopeia Drug Discovery, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040186142-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION PHARMACOPEIA, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004033440-A1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | CCR2, ACKR3, CX3CR1 | KEAP1 781/4885CA2 1861/4885CA1 1339/4885 |
| US-20060025453-A1 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | CCR2, CXCR1, CXCR2 | KEAP1 518/4885CA2 657/4885CA1 452/4885 |
| US-20040186142-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | KEAP1 296/4885CA2 1738/4885CA1 1189/4885 |
| US-20060014794-A1 | CXCR1 and CXCR2 chemokine antagonists | CXCR1, CXCR2, CXCR5 | KEAP1 1332/4885CA2 2801/4885CA1 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.